News

ProteLight Pharma Focuses on R & D of Antimicrobial Peptide New Drugs -- Declare War on “Superbugs”

2018-09-05

September 3th, 2019, “Economic Daily News•China Economic Net” published an article named “ProteLight focuses on R & D of antimicrobial peptide new drugs -- declare war on superbugs", it tells the hard R&D process about Dr. Yuxin Chen, the Chairman of Board of ProteLight Pharma, lead his team to develop antimicrobial peptide new drugs.

 

Report links

http://paper.ce.cn/jjrb/html/2018-09/03/content_371605.htm

Previous article

ProteLight Pharma Completed B Round Capital Raising of RMB 133 million

Next article

Dr. Yuxin Chen Received Peptide Application Special Award

/news_detail/49.html

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

—

2024-10-26

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

■

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

■

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

■

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

■

Congratulations to the company for passing the ISO9001 quality management system certification

■

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China